Schema della sezione

  • MEDSynth is a Medicinal Chemistry group funded in the late 2012 by Marco Lolli and Donatella Boschi, two members of the Dep. Science and Drug Technology (DSTF) of the University of Torino (IT).  The MEDSynth group is able to offer a complete technological platform, from the in silico design, throughout the synthesis until the in vitro / in vivo pharmacological characterization, for the design of preclinical drug candidates. 

    See here www.medsynth.unito.it  for details

    Reinforced by a strong background based on around twenty years in Medicinal and Heterocyclic chemistry experience, our major research interest can be found in the design of small active molecules effective in Cancer and Neglected diseases. At the present, MEDSynth research is major focused on:

    •          Acute Myeloid Leukemia (AML).

    •          Immunosuppression

    •          Gaba and Glutaminergic neutrasmission

    •          Prostatic Cancer

    •          Neglected diseases (Malaria, Leihmania, …)